June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The design of a randomized clinical trial on the neuroprotective properties of erythropoietin in optic neuritis: Treatment of Optic Neuritis with Erythropoietin (TONE)
Author Affiliations & Notes
  • Wolf Lagrèze
    Ophthalmology, University of Freiburg, Freiburg im Breisgau, Germany
  • Ricarda Diem
    Neurology, University Heidelberg, Heidelberg, Germany
  • Footnotes
    Commercial Relationships Wolf Lagrèze, None; Ricarda Diem, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5538. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wolf Lagrèze, Ricarda Diem, ; The design of a randomized clinical trial on the neuroprotective properties of erythropoietin in optic neuritis: Treatment of Optic Neuritis with Erythropoietin (TONE). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5538.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: After successful completion of the VISION PROTECT pilot trial (NCT00355095) providing the first morphologic OCT-based evidence for neuroprotection with erythropoietin in optic neuritis, the German government has recently approved a subsequent, full-scale, nationwide randomized controlled clinical trial (NCT01962571), whose design we intend to present here.

Methods: A power analysis based on publications on the natural course and thinning of the peripapillary retinal nerve fiber layer after optic neuritis yielded a number of 47 patients in each treatment arm of a placebo-controlled, randomized, double-blind clinical trial to demonstrate a treatment effect of 50% reduction of nerve fiber loss with an α of 0.05 and β of 0.80.

Results: Recruitment of TONE has commenced in December 2014. Patients are randomized on either i.v. placebo or intravenous 33.000 IU i.v. erythropoietin as an add-on to a 3 day course of i.v. megadose methylprednisolone. Primary outcome measure is the peripapillary retinal nerve fiber layer thickness determined with the NSITE 6.0 software of the Spectralis®-OCT. Secondary analyses comprise retinal layer segmentation. Functional measures are ETDRS-chart based visual acuity at 2.5% and 100% contrast, contrast sensitivity, volumetric analysis of the visual field defect determined by the German Adaptive Threshold Estimation (GATE) algorithm, VEP-latencies and vision-related quality of life. Results are expected after completion presumably in 2017. A 1.5 year open label follow-up shall provide further insights of erythropoietin effects with regard to MS-progression.

Conclusions: A positive outcome of the TONE-Trial would not only provide new treatment options for patients with optic neuritis, but might promote further clinical research in multiple sclerosis.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×